Vertex Crispr Agreement

CRISPR Therapeutics Investor Contact:Susan Kim, CTX001 is being developed as part of a co-development and co-marketing agreement between CRISPR Therapeutics and Vertex. Of the genetic editing methods studied/evaluated for TDT and SCD, CTX001 is the most advanced in clinical development. About CRISPR Therapeutics CRISPR Therapeutics` mission is to develop transgenic drugs for patients with serious illnesses. Our therapeutic approach aims to cure diseases at the molecular level with the revolutionary genetic editing technology called CRISPR-Cas9. With our multidisciplinary team of world-renowned academics, drug developers and clinicians, we are uniquely positioned to transform CRISPR-Cas9 technology into human therapeutics. We have licensed our scientific founder, Dr. Emmanuelle Charpentier, for the use of humanotherapeutics, of our scientific founder. We are headquartered in Basel, Switzerland, with research and development operations in Cambridge, Massachusetts and offices in London, UK. CTX001 will be jointly developed by Vertex and CRISPR as part of a co-development and co-marketing agreement originally signed in 2015. TDT/SCD gene therapy is the first treatment from the joint research program. About CRISPR TherapeuticsCRISPR Therapeutics is a leading genetic publishing company focused on the development of transgenic drugs for serious diseases with its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary genetic editing technology that enables precise and targeted modifications of genomic DNA.

CRISPR Therapeutics has established a portfolio of therapeutic programs in a wide range of disease areas such as hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic cooperation with leading companies such as Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its U.S. subsidiaries CRISPR Therapeutics, Inc. and Research and Development in Cambridge, Massachusetts, as well as branches in San Francisco, California and London, UK. For more information, see CRISPR Therapeutics Forward-Looking StatementThis press release may contain a series of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements by Dr. Kulkarni, Dr. Kewalramani and Dr. Frangoul in this press release, as well as statements on CRISPR Therapeutics` expectations regarding one or all of the following: (i) the safety, efficacy and clinical progress of THE various CRISPR Therapeutics clinical programs, including CTX001; (ii) the status of clinical trials (including, but not limited, to the expected date of data sharing) regarding candidates for products developed by CRISPR Therapeutics and its collaborators, including expectations regarding the data presented in this press release, at the ash annual meeting and exhibition and in the NEJM article; (iii) the expected benefits of the collaboration of CRISPR Therapeutics; and (iv) the therapeutic value, development and commercial potential of CRISPR/Cas9 gene technologies and therapies.

Comments are closed.